<table>
<thead>
<tr>
<th>Study ID</th>
<th>Protocol Code</th>
<th>IRB#</th>
<th>Sponsor</th>
<th>Principal Investigator</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>McG 0302</td>
<td>[CPTAIV-0020-411]</td>
<td>A02-M09-03A</td>
<td>Pharmacia</td>
<td>Dr. W. Miller</td>
<td>TERMINATED</td>
</tr>
<tr>
<td>McG 0302pk</td>
<td>[CPTAIV-0020-366]</td>
<td></td>
<td>Pharmacogenics</td>
<td>Dr. W. Miller</td>
<td>TERMINATED</td>
</tr>
<tr>
<td>McG 0303</td>
<td>[THAL-MM-003]</td>
<td></td>
<td>Celgene Corporation</td>
<td>Dr. C. Shustik</td>
<td>TERMINATED</td>
</tr>
<tr>
<td>McG 0304</td>
<td>[CC-5013-MM-009]</td>
<td></td>
<td>Celgene Corporation</td>
<td>Dr. C. Shustik</td>
<td>CLOSED</td>
</tr>
<tr>
<td>McG 0306</td>
<td>[NO16967]</td>
<td></td>
<td>Roche Canada</td>
<td></td>
<td>TERMINATED</td>
</tr>
<tr>
<td>McG 0308</td>
<td>[201]</td>
<td></td>
<td>Ark Therapeutics</td>
<td>Dr. B. Gagnon</td>
<td>TERMINATED</td>
</tr>
</tbody>
</table>

Updated November 19, 2008
-McG 0309- [20020163]  IRB#: A05-M40-03A
Multicentre, Double-blind, Randomised Phase 2 Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia.
Amgen Canada
Dr. P. Laneuville  TERMINATED

-McG 0310- [H7X-MC-JVAI]  IRB#: A06-M49-03A
A Phase 1 ½ Trial of LY900003 (3-Day Pretreatment Followed by 7-Day Infusion) Plus Gemcitabine and Cisplatin in Patients with Advanced, Previously Untreated Non-Small Cell Lung Cancer.
Eli Lilly
Dr. V. Hirsh  TERMINATED

-McG 0311- [EFC4972 Xenox]  IRB#: A09-M62-03A
A multicenter randomized double-blind placebo controlled phase III study of the efficacy of Xaliproden in reducing the neurotoxicity of the Oxaliplatin and 5-FU/LV combination in first-line treatment of patients with metastatic colorectal carcinoma (MCRC)
Sanofi-Synthelabo
Dr. L. Panasci  TERMINATED

-McG 0312- [NA17101C]  IRB#: A09-M57-03B
An Open-Label, Randomized, Multicenter, Phase II Study to Determine hemoglobin dose response, Safety and Pharmacokinetic Profile of RO-503821 Given Subcutaneously Once Every 3 Weeks to Anemic Patients with Stage IIIB or IV Non-Small Cell Lung Carcinoma Receiving Antineoplastic Therapy.
Hoffman-La Roche
Dr. Vera Hirsh  TERMINATED

-McG 0313- [BCIRG 103 (1839IL/0219)]  IRB#: A12-M63-03A
A Presurgical Study to Evaluate Molecular Alterations That Occur in Human Breast Cancer Tissue and Normal Skin After Short Term Exposure to ZD 1839 (Iressa) and to Correlate These Alterations with Pharmacokinetic Parameters.
BCIRG
Dr. Gerald Batist  TERMINATED

-McG 0314- [IMN1207-003]  IRB #: A06-M48-03A
IMN1207 Versus Casein in the Prevention of Wasting Over Six Months During, or Following Chemotherapy, Radiation or Surgery in the Treatment of Colorectal or Non-Small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind Study.
Immunotec Medical Corporation
Dr. Neil MacDonald  TERMINATED

-McG 0317- [BO17072]  IRB#: A10-M73-03A
An Open-Label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Rituximab Plus Fludarabine and Cyclophosphamide (FCR) Versus Fludarabine and Cyclophosphamide Alone (FC) in Previously Treated Patients With CD20 Positive B-Cell Chronic Lymphocytic Leukemia (CLL)
Hoffman-La Roche Pharmaceuticals
Dr. L. Shustik  TERMINATED
-McG 0318-  
Updated November 19, 2008
Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of Gemcitabine-Cisplatin Combined with Two Different Doses of LY293111 or Placebo in Patients with Stage IIIB or IV Non-Small Cell Lung Cancer.

Eli Lilly Canada
Dr. Vera Hirsh
TERMINATED

-McG 0319-  
A Phase III, Randomized, Open-Label Study of IV Edotecarin vs. Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme That Has Progressed/Recurred After Alkylator-based (Neo)Adjuvant Chemotherapy.

Pharmacia
Dr. Kavan
TERMINATED

- McG 0322-  
Promune TM (CPG 7909 Injection) in Combination with Chemotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer, a Randomized, Multi-Center, Controlled, Phase 2 Study.

Coley Pharmaceutical Group
Dr. Vera Hirsh
TERMINATED

- McG 0323-  
A Randomized Double-Blind, Placebo-Controlled, Phase III Study of Oxaliplatin/5-Fluorouracil/Leucovorin with PTK787/222584 or Placebo in Patients with Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum

Novartis
Dr. Wilson Miller
TERMINATED

- McG 0325-  
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study in Patients with metastatic Adenocarcinoma of the Colon or Rectum who are Receiving First-Line Chemotherapy with Oxaliplatin/5-Fluorouracil/Leucovorin and PTK787/222584.

Novartis
Dr. Wilson Miller
TERMINATED

- McG 0328-  
A Phase II Study Evaluating the Efficacy and Safety of ABT-751 in Patients with Renal Cell Carcinoma.

Abbott
Dr. Simon Tanguay
TERMINATED

- McG 0329-  
A Phase III, Randomized, Stratified, Parallel-Group, Multicentre, Comparative Study of ZD1839 (Iressa®) 250mg and 500mg versus Methotrexate for Previously Treated Patients with Squamous Cell Carcinoma of the Head and Neck

AstraZeneca
Dr. Michael Pollak
TERMINATED
A Phase II, Open-I, Study of CAELYX and Carboplatin in Platinum-Sensitive Relapsed Epithelial Ovarian Cancer.

Schering Canada

Dr. Wilson Miller

TERMINATED